1. Clinical manifestations:(AKI vs. non-AKI)-Dyspnea (70.7% vs. 65.0%); Cough (80.5% vs. 75.0%); Fever (82.9% vs. 95.0%);2. Initial laboratory data:-Platelets (145.0 vs. 176.5, p=0.03); Lymphocytes (0.50 vs. 0.65, p=0.02); SCr (104.0 vs. 65.5, p<0.001); Elevated SCr (51.2 % vs. 7.5%, p<0.001); Cystatin C (1.74 vs. 1.06, p<0.001); BUN (12.5 vs. 7.1, p<0.001); Serum uric acid (289.5 vs. 164.0, p<0.001); IL-6 (100.4 vs. 36.8, p=0.01); PT (17.2 vs. 16.0, p=0.04); INR (1.40 vs. 1.26, p=0.02); NT-proBNP (1902.0 vs. 843.0, p=0.03). This evidence concerns the gene CST3 and acute kidney injury.